Encycle Therapeutics raises over $2.5 mln to advance drug platform

Biotechnology startup Encycle Therapeutics Inc recently secured more than $2.5 million from undisclosed investors. The capital infusion is intended to support the company's drug development platform, which is focused on treating inflammatory bowel disease and related conditions. Encycle was founded two years ago by Dr. Andrei Yudin of the University of Toronto in partnership with commercialization agent MaRS Innovation. It is currently collaborating on its research project with MaRS, the Institute for Research in Immunology and Cancer-Commercialization of Research and the Université de Montréal.

CanadaNorth AmericaBriefs